Back to Search
Start Over
Legumain is a paracrine regulator of osteoblast differentiation and mediates the inhibitory effect of TGF-β1 on osteoblast maturation.
- Source :
-
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Sep 19; Vol. 15, pp. 1445049. Date of Electronic Publication: 2024 Sep 19 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Transforming growth factor-beta 1 (TGF-β1) is a critical regulator of skeletal homeostasis and has diverse effects on osteoblastogenesis. To date, the mechanisms behind the intriguing inhibitory effect of TGF-β1 on osteoblast maturation are not fully understood. Here, we demonstrate a novel mechanism by which TGF-β1 modulates osteoblast maturation through the lysosomal protease legumain. We observed that addition of TGF-β1 to osteogenic cultures of human bone marrow derived mesenchymal stromal (stem) cells enhanced legumain activity and secretion, in-spite of decreased legumain mRNA expression, suggesting post-transcriptional regulation. We further showed that osteogenic cells internalize and activate prolegumain, associated with inhibited osteoblast maturation, revealing legumain as a paracrine regulator of osteoblast maturation. Interestingly, TGF-β1 treatment exacerbated legumain internalization and activity, and showed an additive effect on legumain-induced inhibition of osteoblast maturation. Importantly, pharmacological inhibition of legumain abolished the inhibitory effect of TGF-β1 on osteoblast maturation. Our findings reveal that TGF-β1 inhibits osteoblast maturation by stimulating secretion and activity of endogenous legumain, as well as enhancing internalization and activation of extracellular prolegumain. Therefore, our study provides a deeper understanding of the complex regulation of osteoblastogenesis and unveils a novel TGF-β1-legumain axis in regulation of osteoblast maturation, offering novel insights for possible therapeutic interventions related to bone diseases associated with aberrant TGF-β1 signaling.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.<br /> (Copyright © 2024 Forbord, Lunde, Bosnjak-Olsen, Johansen, Solberg and Jafari.)
- Subjects :
- Humans
Paracrine Communication drug effects
Cells, Cultured
Osteoblasts metabolism
Osteoblasts drug effects
Osteoblasts cytology
Transforming Growth Factor beta1 pharmacology
Transforming Growth Factor beta1 metabolism
Cell Differentiation drug effects
Cysteine Endopeptidases metabolism
Cysteine Endopeptidases genetics
Mesenchymal Stem Cells drug effects
Mesenchymal Stem Cells metabolism
Mesenchymal Stem Cells cytology
Osteogenesis drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1664-2392
- Volume :
- 15
- Database :
- MEDLINE
- Journal :
- Frontiers in endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 39363898
- Full Text :
- https://doi.org/10.3389/fendo.2024.1445049